CurisCRIS
CRIS
About: Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Employees: 33
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
17.25% more ownership
Funds ownership: 37.87% [Q4 2024] → 55.12% (+17.25%) [Q1 2025]
0% more funds holding
Funds holding: 40 [Q4 2024] → 40 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0% less capital invested
Capital invested by funds: $9.81M [Q4 2024] → $9.8M (-$10K) [Q1 2025]
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
553%
upside
Avg. target
$16.50
573%
upside
High target
$17
594%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 594%upside $17 | Buy Assumed | 19 May 2025 |
HC Wainwright & Co. Edward White | 553%upside $16 | Buy Maintained | 31 Mar 2025 |
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass. , May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant").
Neutral
Seeking Alpha
1 month ago
Curis, Inc. (CRIS) Q1 2025 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Ahmed Hamdy - Chief Medical Officer Jonathan Zung - Chief Development Officer Conference Call Participants Li Watsek - Cantor Fitzgerald Kripa Devarakonda - Truist Securities Operator Good morning ladies and gentlemen and welcome to the Curis Provides First Quarter 2025 Business Update Conference Call. At this time, all lines are in listen-only mode.
Negative
Zacks Investment Research
1 month ago
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
Curis (CRIS) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $2.05 per share a year ago.
Neutral
PRNewsWire
1 month ago
Curis Provides First Quarter 2025 Business Update
Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Neutral
PRNewsWire
1 month ago
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
LEXINGTON, Mass. , April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m.
Neutral
PRNewsWire
2 months ago
Curis to Present at Upcoming Healthcare Conference in April
LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.
Neutral
Seeking Alpha
2 months ago
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President and CEO Jonathan Zung - Chief Development Officer Conference Call Participants Sean McCutcheon - Raymond James Li Watsek - Cantor Fitzgerald Ed White - H.C. Wainwright Operator Good morning, and welcome to Curis's Fourth Quarter 2024 Business Update Call.
Neutral
PRNewsWire
2 months ago
Curis Provides Fourth Quarter 2024 Business Update
FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Neutral
PRNewsWire
2 months ago
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m.
Neutral
PRNewsWire
6 months ago
Curis Announces Additional Data from TakeAim Leukemia Study
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim Leukemia study (CA-4948-102) in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) at the 66th ASH annual meeting.
Charts implemented using Lightweight Charts™